Literature DB >> 25072962

Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis.

Tobias Wagner1, Peter Brand2, Thorsten Heinzel2, Oliver H Krämer3.   

Abstract

Histone deacetylase 2 (HDAC2) regulates biological processes by deacetylation of histones and non-histone proteins. HDAC2 is overexpressed in numerous cancer types, suggesting general cancer-relevant functions of HDAC2. In human tumors the TP53 gene encoding p53 is frequently mutated and wild-type p53 is often disarmed. Molecular pathways inactivating wild-type p53 often remain to be defined and understood. Remarkably, current data link HDAC2 to the regulation of the tumor suppressor p53 by deacetylation and to the maintenance of genomic stability. Here, we summarize recent findings on HDAC2 overexpression in solid and hematopoietic cancers with a focus on mechanisms connecting HDAC2 and p53 in vitro and in vivo. In addition, we present an evidence-based model that integrates molecular pathways and feedback loops by which p53 and further transcription factors govern the expression and the ubiquitin-dependent proteasomal degradation of HDAC2 and of p53 itself. Understanding the interactions between p53 and HDAC2 might aid in the development of new therapeutic approaches against cancer.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; HDAC inhibitors; HDAC2; RLIM; Sumoylation; p53

Mesh:

Substances:

Year:  2014        PMID: 25072962     DOI: 10.1016/j.bbcan.2014.07.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  28 in total

1.  Up-regulation of HDAC9 promotes cell proliferation through suppressing p53 transcription in osteosarcoma.

Authors:  Yu-Xin Zhao; Yi-Sheng Wang; Qi-Qing Cai; Jia-Qiang Wang; Wei-Tao Yao
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.

Authors:  Samuel Bouchet; Camille Linot; Dusan Ruzic; Danica Agbaba; Benoit Fouchaq; Joëlle Roche; Katarina Nikolic; Christophe Blanquart; Philippe Bertrand
Journal:  ACS Med Chem Lett       Date:  2019-05-09       Impact factor: 4.345

3.  Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.

Authors:  Hongyu Gao; Huihan Wang; Wei Yang
Journal:  Int J Hematol       Date:  2017-03-18       Impact factor: 2.490

Review 4.  Combination Therapies Targeting HDAC and IKK in Solid Tumors.

Authors:  Ivana Vancurova; Mohammad M Uddin; Yue Zou; Ales Vancura
Journal:  Trends Pharmacol Sci       Date:  2017-12-09       Impact factor: 14.819

5.  HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.

Authors:  Shenglei Li; Feng Wang; Yunhui Qu; Xiaoqi Chen; Ming Gao; Jianping Yang; Dandan Zhang; Na Zhang; Wencai Li; Hongtao Liu
Journal:  Oncol Lett       Date:  2016-11-25       Impact factor: 2.967

Review 6.  The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.

Authors:  Mariana Matias; Jacinta O Pinho; Maria João Penetra; Gonçalo Campos; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

7.  Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU.

Authors:  Ruihao Zhou; Juan Wu; Xiaofeng Tang; Xin Wei; Cheng Ju; Feifei Zhang; Jun Sun; Deyong Shuai; Zhiping Zhang; Qiong Liu; Xiao-Bin Lv
Journal:  Oncol Lett       Date:  2018-05-31       Impact factor: 2.967

8.  Targeting epigenetic regulators in the treatment of T-cell lymphoma.

Authors:  Nada Ahmed; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2020-01-22       Impact factor: 2.929

9.  HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.

Authors:  N Stojanovic; Z Hassan; M Wirth; P Wenzel; M Beyer; C Schäfer; P Brand; A Kroemer; R H Stauber; R M Schmid; A Arlt; A Sellmer; S Mahboobi; R Rad; M Reichert; D Saur; O H Krämer; G Schneider
Journal:  Oncogene       Date:  2016-10-10       Impact factor: 9.867

10.  Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis.

Authors:  Luting Chen; Yuchang Fei; Yurong Zhao; Quan Chen; Peifeng Chen; Lei Pan
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.